Alain Baulard
Overview
Explore the profile of Alain Baulard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sury A, Maex M, Baulard A, Bhattacharyya R, Depickere S, Hung D, et al.
EBioMedicine
. 2025 Feb;
113:105611.
PMID: 40010155
Background: Efficient management of drug-resistant tuberculosis relies on fast diagnostics. To accelerate phenotypic drug susceptibility testing [pDST] for Mycobacterium tuberculosis [TB], we introduce TRACeR-TB, a test that infers drug resistance...
2.
Gedeon A, Yab E, Dinut A, Sadowski E, Capton E, Dreneau A, et al.
iScience
. 2024 Oct;
27(10):110967.
PMID: 39429773
Antimicrobial resistance remains a persistent and pressing public health concern. Here, we describe the synthesis of original triazole-containing inhibitors targeting the DNA gyrase, a well-validated drug target for developing new...
3.
Gries R, Chhen J, van Gumpel E, Theobald S, Sonnenkalb L, Utpatel C, et al.
Cell Chem Biol
. 2024 Jan;
31(4):699-711.e6.
PMID: 38181799
Drug-resistant Mycobacterium tuberculosis (Mtb) remains a major public health concern requiring complementary approaches to standard anti-tuberculous regimens. Anti-virulence molecules or compounds that enhance the activity of antimicrobial prodrugs are promising...
4.
Maitre T, Baulard A, Aubry A, Veziris N
Infect Dis Now
. 2023 Oct;
54(1):104807.
PMID: 37839674
Antibiotic-resistant tuberculosis continues to be one of the major threats to global tuberculosis control. After a hiatus of over 40 years in antituberculosis drug development, the last decade has seen...
5.
Antraygues K, Compagne N, Ruggieri F, Djaout K, Edoo Z, Eveque M, et al.
Pharmaceuticals (Basel)
. 2022 Apr;
15(4).
PMID: 35455385
The restrictions posed by the COVID-19 pandemic obliged the French Society for Medicinal Chemistry (Société de chimie thérapeutique) and the French Microbiology Society (Société Française de Microbiologie) to organize their...
6.
Zeng S, Constant P, Yang D, Baulard A, Lefevre P, Daffe M, et al.
Front Microbiol
. 2019 Jun;
10:1149.
PMID: 31244785
Biofilm formation is a survival strategy for microorganisms facing a hostile environment. Under biofilm, bacteria are better protected against antibacterial drugs and the immune response, increasing treatment difficulty, as persistent...
7.
Pastor A, Machelart A, Li X, Willand N, Baulard A, Brodin P, et al.
Org Biomol Chem
. 2019 May;
17(20):5129-5137.
PMID: 31073555
Ethionamide (ETH) is one of the most widely used second-line chemotherapeutic drugs for the treatment of multi-drug-resistant tuberculosis. The bioactivation and activity of ETH is dramatically potentiated by a family...
8.
Costa-Gouveia J, Pancani E, Jouny S, Machelart A, Delorme V, Salzano G, et al.
Sci Rep
. 2018 May;
8(1):7596.
PMID: 29748596
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
9.
Song O, Queval C, Iantomasi R, Delorme V, Marion S, Veyron-Churlet R, et al.
EMBO Rep
. 2017 Nov;
19(1):29-42.
PMID: 29141986
The interaction of (Mtb) with pulmonary epithelial cells is critical for early stages of bacillus colonization and during the progression of tuberculosis. Entry of Mtb into epithelial cells has been...
10.
Costa-Gouveia J, Pancani E, Jouny S, Machelart A, Delorme V, Salzano G, et al.
Sci Rep
. 2017 Jul;
7(1):5390.
PMID: 28710351
Tuberculosis (TB) is a leading infectious cause of death worldwide. The use of ethionamide (ETH), a main second line anti-TB drug, is hampered by its severe side effects. Recently discovered...